On January 29, 2026, BioMarin Pharmaceutical Inc. announced a $850 million offering of senior unsecured notes due 2034 and details of a $2 billion loan for acquiring Amicus Therapeutics. This significant financing is intended to fund the acquisition and associated expenses, indicating a major step in their growth strategy.